Pamela Wapnick, M.B.A.

Pamela Wapnick, M.B.A.

Chief Financial OfficeratMetagenomi Therapeutics· In proxies 2023–2025

Pay in FY2025-74% from the year before · Metagenomi Therapeutics stock -55.1% the same year

Pamela Wapnick, M.B.A. was paid $935.0K in FY2025 (Dec), down 74%. Metagenomi Therapeutics stock fell 55.1% that year.

Pay$100 in the stock at the end of FY24 → $45
Pay is from the Summary Compensation Table of each Metagenomi Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Metagenomi TherapeuticsPublic company · 3 yr
    • Chief Financial Officer2023 – Present · 3 yrStock in role -92%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?